0001564590-22-005219.txt : 20220215 0001564590-22-005219.hdr.sgml : 20220215 20220215161605 ACCESSION NUMBER: 0001564590-22-005219 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220215 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220215 DATE AS OF CHANGE: 20220215 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Adaptive Biotechnologies Corp CENTRAL INDEX KEY: 0001478320 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 270907024 STATE OF INCORPORATION: WA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38957 FILM NUMBER: 22639359 BUSINESS ADDRESS: STREET 1: 1165 EASTLAKE AVE E CITY: SEATTLE STATE: WA ZIP: 98109 BUSINESS PHONE: 206-659-0067 MAIL ADDRESS: STREET 1: 1165 EASTLAKE AVE E CITY: SEATTLE STATE: WA ZIP: 98109 FORMER COMPANY: FORMER CONFORMED NAME: Adaptive TCR Corp DATE OF NAME CHANGE: 20091209 8-K 1 adpt-8k_20220215.htm 8-K adpt-8k_20220215.htm
false 0001478320 0001478320 2022-02-15 2022-02-15

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 15, 2022

 

ADAPTIVE BIOTECHNOLOGIES CORPORATION

(Exact name of Registrant as Specified in Its Charter)

 

 

Washington

001-38957

27-0907024

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

 

 

 

1165 Eastlake Avenue East

Seattle, Washington

 

98109

(Address of Principal Executive Offices)

 

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (206) 659-0067

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common stock, par value $0.0001 per share

 

ADPT

 

The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

 

 

 

 


 

 

Item 2.02

Results of Operations and Financial Condition.

On February 15, 2022, Adaptive Biotechnologies Corporation (the “Company”) issued a press release regarding the Company’s financial results for the quarter and fiscal year ended December 31, 2021. A copy of the press release is attached as Exhibit 99.1 and incorporated herein by reference.

The information in this Item 2.02 and the press release attached as Exhibit 99.1 hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

As previously announced, the Company’s Chief Financial Officer, Mr. Chad Cohen, is resigning effective February 15, 2022, upon the filing of the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. On February 15, 2022, the Board of Directors of the Company appointed Mr. Kyle Piskel, the Company’s Principal Accounting Officer, as interim Chief Financial Officer effective concurrent with Mr. Cohen’s resignation, and Mr. Piskel will serve as the Company’s principal financial officer.  

Mr. Piskel’s biographical details are included in the Company’s Current Report on Form 8-K, filed on November 3, 2021, which are incorporated herein by reference.  

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit

Number

 

Description

99.1

 

Press Release dated February 15, 2022

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 


 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

Adaptive Biotechnologies Corporation

 

 

 

 

Date: February 15, 2022

 

By:

/s/ Chad Cohen

 

 

 

Chad Cohen

 

 

 

Chief Financial Officer

 

 

 

EX-99.1 2 adpt-ex991_6.htm EX-99.1 adpt-ex991_6.htm

EXHIBIT 99.1

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2021 Financial Results

 

 

SEATTLE, Feb. 15, 2022 (GLOBE NEWSWIRE) – Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the fourth quarter and full year ended December 31, 2021.

 

“We finished the year strong with revenue increasing 57% year over year, driven by growth in both our sequencing and development revenue categories,” said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. “As we move into 2022, I am encouraged by the momentum and the multiple shots on goal across our businesses, which could positively inflect the trajectory of the company.”

Recent Highlights

 

Revenue of $37.9 million for the fourth quarter and $154.3 million for the full year of 2021, representing a 26% increase and 57% increase, respectively, over the corresponding periods in 2020.

 

clonoSEQ clinical sequencing volume increased 41% to 6,356 clinical tests delivered in the fourth quarter of 2021, compared to the fourth quarter of 2020 and ended the year with 22,516 clinical tests delivered, up 48% versus 2020.

 

Recognized $10.0 million in MRD regulatory milestones resulting from pharmaceutical partners who used data from our MRD assay to support their respective drug approvals.

 

Genentech selected TCR candidate targeting a shared cancer neoantigen to progress as a potential therapeutic product candidate.

 

Received Emergency Use Authorization (EUA) from FDA for T-Detect™ COVID to confirm recent or prior COVID-19 infection with over 30,000 tests ordered.

 

Confirmed T-Detect signals in Crohn’s disease and Multiple Sclerosis and identified signals in Ulcerative Colitis and Rheumatoid Arthritis.

Fourth Quarter 2021 Financial Results

Revenue was $37.9 million for the quarter ended December 31, 2021, representing a 26% increase from the fourth quarter in the prior year. Sequencing revenue was $23.1 million for the quarter, representing an 81% increase from the fourth quarter in the prior year. Development revenue was $14.9 million for the quarter, representing a 15% decrease from the fourth quarter in the prior year.

Operating expenses were $99.5 million for the fourth quarter of 2021, compared to $74.4 million in the fourth quarter of the prior year, representing an increase of 34%.

Net loss was $61.4 million for the fourth quarter of 2021, compared to $44.6 million for the same period in 2020.

Adjusted EBITDA (non-GAAP) was a loss of $44.9 million for the fourth quarter of 2021, compared to a loss of $34.6 million for the fourth quarter of the prior year.


Full Year 2021 Financial Results

Revenue was $154.3 million for the year ended December 31, 2021, representing a 57% increase from the prior year. Sequencing revenue was $78.9 million in 2021, representing a 90% increase from 2020. Development revenue was $75.4 million in 2021, representing a 32% increase from the prior year.

Operating expenses for 2021 were $363.3 million, compared to $251.2 million for 2020, representing an increase of 45%.

Net loss was $207.3 million in 2021, compared to $146.2 million in 2020.

Adjusted EBITDA (non-GAAP) was a loss of $151.7 million for 2021, compared to a loss of $119.6 million in the prior year.

Cash, cash equivalents and marketable securities was $570.2 million as of December 31, 2021.

2022 Financial Guidance

Management will provide the 2022 outlook during the conference call scheduled to discuss the 2021 financial results.

Webcast and Conference Call Information

Adaptive Biotechnologies will host a conference call to discuss its fourth quarter and full year 2021 financial results after market close on Tuesday, February 15, 2022 at 4:30 PM Eastern Time. The conference call can be accessed at http://investors.adaptivebiotech.com. The webcast will be archived and available for replay at least 90 days after the event.

About Adaptive Biotechnologies

Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics and drug discovery. We have three commercial products and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune disorders, and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.

Forward-Looking Statements

This press release contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts and other matters regarding our business strategies, use of capital, results of operations and financial position and plans and objectives for future operations.  


In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

Use of Non-GAAP Financial Measure

To supplement our unaudited consolidated statements of operations and unaudited consolidated balance sheets, which are prepared in conformity with generally accepted accounting principles in the United States of America (“GAAP”), this press release also includes references to unaudited Adjusted EBITDA, which is a non-GAAP financial measure that we define as net loss attributable to Adaptive Biotechnologies Corporation adjusted for interest and other income, net, income tax (expense) benefit, depreciation and amortization and share-based compensation expenses. We have provided a reconciliation of net loss attributable to Adaptive Biotechnologies Corporation, the most directly comparable GAAP financial measure, to Adjusted EBITDA at the end of this press release.

Management uses Adjusted EBITDA to evaluate the financial performance of our business and the effectiveness of our business strategies. We present Adjusted EBITDA because we believe it is frequently used by analysts, investors and other interested parties to evaluate companies in our industry and it facilitates comparisons on a consistent basis across reporting periods. Further, we believe it is helpful in highlighting trends in our operating results because it excludes items that are not indicative of our core operating performance.

Adjusted EBITDA has limitations as an analytical tool and you should not consider it in isolation or as a substitute for analysis of our results as reported under GAAP. We may in the future incur expenses similar to the adjustments in the presentation of Adjusted EBITDA. In particular, we expect to incur meaningful share-based compensation expense in the future. Other limitations include that Adjusted EBITDA does not reflect:

 

all expenditures or future requirements for capital expenditures or contractual commitments;

 

changes in our working capital needs;

 

income tax (expense) benefit, which may be a necessary element of our costs and ability to operate;

 

the costs of replacing the assets being depreciated and amortized, which will often have to be replaced in the future;

 

the non-cash component of employee compensation expense; and

 

the impact of earnings or charges resulting from matters we consider not to be reflective, on a recurring basis, of our ongoing operations.

In addition, Adjusted EBITDA may not be comparable to similarly titled measures used by other companies in our industry or across different industries.


ADAPTIVE MEDIA
Laura Cooper
205-908-5603
media@adaptivebiotech.com

ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations

201-396-1687
Carrie Mendivil, Gilmartin Group
investors@adaptivebiotech.com

 


 

 

Adaptive Biotechnologies

Consolidated Statements of Operations

(in thousands, except share and per share amounts)

(unaudited)

 

 

 

Three Months Ended December 31,

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

Revenue

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sequencing revenue

 

$

23,061

 

 

$

12,709

 

 

$

78,896

 

 

$

41,439

 

Development revenue

 

 

14,869

 

 

 

17,476

 

 

 

75,448

 

 

 

56,943

 

Total revenue

 

 

37,930

 

 

 

30,185

 

 

 

154,344

 

 

 

98,382

 

Operating expenses

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of revenue

 

 

14,356

 

 

 

6,222

 

 

 

49,301

 

 

 

22,530

 

Research and development

 

 

34,699

 

 

 

35,831

 

 

 

142,343

 

 

 

116,072

 

Sales and marketing

 

 

26,696

 

 

 

18,545

 

 

 

95,465

 

 

 

61,358

 

General and administrative

 

 

23,346

 

 

 

13,398

 

 

 

74,502

 

 

 

49,536

 

Amortization of intangible assets

 

 

429

 

 

 

428

 

 

 

1,699

 

 

 

1,703

 

Total operating expenses

 

 

99,526

 

 

 

74,424

 

 

 

363,310

 

 

 

251,199

 

Loss from operations

 

 

(61,596

)

 

 

(44,239

)

 

 

(208,966

)

 

 

(152,817

)

Interest and other income, net

 

 

239

 

 

 

785

 

 

 

1,668

 

 

 

6,590

 

Income tax expense

 

 

 

 

 

(1,116

)

 

 

 

 

 

 

Net loss

 

 

(61,357

)

 

 

(44,570

)

 

 

(207,298

)

 

 

(146,227

)

Add: Net (income)  loss attributable to noncontrolling interest

 

 

(76

)

 

 

 

 

 

19

 

 

 

 

Net loss attributable to Adaptive Biotechnologies Corporation

 

$

(61,433

)

 

$

(44,570

)

 

$

(207,279

)

 

$

(146,227

)

Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted

 

$

(0.43

)

 

$

(0.33

)

 

$

(1.48

)

 

$

(1.11

)

Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted

 

 

141,228,918

 

 

 

136,954,148

 

 

 

140,354,915

 

 

 

131,216,468

 


 

Adaptive Biotechnologies

Consolidated Balance Sheets
(in thousands, except share and per share amounts)

(unaudited)

 

 

 

December 31,

 

 

 

2021

 

 

2020

 

Assets

 

 

 

 

 

 

 

 

Current assets

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

139,065

 

 

$

123,436

 

Short-term marketable securities (amortized cost of $214,115 and $564,036, respectively)

 

 

213,996

 

 

 

564,833

 

Accounts receivable, net

 

 

17,409

 

 

 

10,047

 

Inventory

 

 

19,263

 

 

 

14,063

 

Prepaid expenses and other current assets

 

 

13,015

 

 

 

14,535

 

Total current assets

 

 

402,748

 

 

 

726,914

 

Long-term assets

 

 

 

 

 

 

 

 

Property and equipment, net

 

 

85,262

 

 

 

39,692

 

Operating lease right-of-use assets

 

 

87,678

 

 

 

99,350

 

Long-term marketable securities (amortized cost of $218,163 and $118,429, respectively)

 

 

217,145

 

 

 

118,525

 

Restricted cash

 

 

2,138

 

 

 

2,138

 

Intangible assets, net

 

 

8,526

 

 

 

10,225

 

Goodwill

 

 

118,972

 

 

 

118,972

 

Other assets

 

 

875

 

 

 

598

 

Total assets

 

$

923,344

 

 

$

1,116,414

 

Liabilities and shareholders’ equity

 

 

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

 

 

Accounts payable

 

$

3,307

 

 

$

3,237

 

Accrued liabilities

 

 

9,343

 

 

 

13,162

 

Accrued compensation and benefits

 

 

15,642

 

 

 

11,950

 

Current portion of operating lease liabilities

 

 

5,055

 

 

 

3,529

 

Current portion of deferred revenue

 

 

80,460

 

 

 

73,319

 

Total current liabilities

 

 

113,807

 

 

 

105,197

 

Long-term liabilities

 

 

 

 

 

 

 

 

Operating lease liabilities, less current portion

 

 

106,685

 

 

 

104,333

 

Deferred revenue, less current portion

 

 

98,750

 

 

 

163,618

 

Total liabilities

 

 

319,242

 

 

 

373,148

 

Commitments and contingencies

 

 

 

 

 

 

 

 

Shareholders’ equity

 

 

 

 

 

 

 

 

Preferred stock: $0.0001 par value, 10,000,000 shares authorized at December 31, 2021 and 2020; no shares issued and outstanding at December 31, 2021 and 2020

 

 

 

 

 

 

Common stock: $0.0001 par value, 340,000,000 shares authorized at December 31, 2021 and 2020; 141,393,865 and 137,646,896 shares issued and outstanding at December 31, 2021 and 2020, respectively

 

 

14

 

 

 

14

 

Additional paid-in capital

 

 

1,324,006

 

 

 

1,253,971

 

Accumulated other comprehensive (loss) gain

 

 

(1,137

)

 

 

893

 

Accumulated deficit

 

 

(718,891

)

 

 

(511,612

)

Total Adaptive Biotechnologies Corporation shareholders’ equity

 

 

603,992

 

 

 

743,266

 

Noncontrolling interest

 

 

110

 

 

 

 

Total shareholders’ equity

 

 

604,102

 

 

 

743,266

 

Total liabilities and shareholders’ equity

 

$

923,344

 

 

$

1,116,414

 


 

Adjusted EBITDA

The following table sets forth a reconciliation between our Adjusted EBITDA and net loss attributable to Adaptive Biotechnologies Corporation, the most directly comparable GAAP financial measure, for each of the periods presented (in thousands, unaudited):

 

 

Three Months Ended December 31,

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

Net loss attributable to Adaptive Biotechnologies Corporation

 

$

(61,433

)

 

$

(44,570

)

 

$

(207,279

)

 

$

(146,227

)

Interest and other income, net

 

 

(239

)

 

 

(785

)

 

 

(1,668

)

 

 

(6,590

)

Income tax expense

 

 

 

 

 

1,116

 

 

 

 

 

 

 

Depreciation and amortization expense

 

 

4,849

 

 

 

2,352

 

 

 

13,953

 

 

 

8,472

 

Share-based compensation expense

 

 

11,875

 

 

 

7,243

 

 

 

43,251

 

 

 

24,761

 

Adjusted EBITDA

 

$

(44,948

)

 

$

(34,644

)

 

$

(151,743

)

 

$

(119,584

)

 

GRAPHIC 3 gw0434hn54vo000001.jpg GRAPHIC begin 644 gw0434hn54vo000001.jpg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end EX-101.SCH 4 adpt-20220215.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 5 adpt-20220215_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre Commencement Tender Offer Pre-commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Title of 12(b) Security Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 6 adpt-20220215_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.0.1
Document and Entity Information
Feb. 15, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Feb. 15, 2022
Entity Registrant Name ADAPTIVE BIOTECHNOLOGIES CORPORATION
Entity Central Index Key 0001478320
Entity Incorporation, State or Country Code WA
Entity File Number 001-38957
Entity Tax Identification Number 27-0907024
Entity Address, Address Line One 1165 Eastlake Avenue East
Entity Address, City or Town Seattle
Entity Address, State or Province WA
Entity Address, Postal Zip Code 98109
City Area Code 206
Local Phone Number 659-0067
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, par value $0.0001 per share
Trading Symbol ADPT
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 adpt-8k_20220215_htm.xml IDEA: XBRL DOCUMENT 0001478320 2022-02-15 2022-02-15 false 0001478320 8-K 2022-02-15 ADAPTIVE BIOTECHNOLOGIES CORPORATION WA 001-38957 27-0907024 1165 Eastlake Avenue East Seattle WA 98109 206 659-0067 false false false false Common stock, par value $0.0001 per share ADPT NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.0.1 html 1 118 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.adaptivebiotech.com/20220215/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports adpt-8k_20220215.htm adpt-20220215.xsd adpt-20220215_lab.xml adpt-20220215_pre.xml adpt-ex991_6.htm http://xbrl.sec.gov/dei/2021 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "adpt-8k_20220215.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "adpt-8k_20220215.htm" ] }, "labelLink": { "local": [ "adpt-20220215_lab.xml" ] }, "presentationLink": { "local": [ "adpt-20220215_pre.xml" ] }, "schema": { "local": [ "adpt-20220215.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 118, "memberCustom": 0, "memberStandard": 0, "nsprefix": "adpt", "nsuri": "http://www.adaptivebiotech.com/20220215", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "adpt-8k_20220215.htm", "contextRef": "C_0001478320_20220215_20220215", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.adaptivebiotech.com/20220215/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "adpt-8k_20220215.htm", "contextRef": "C_0001478320_20220215_20220215", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.adaptivebiotech.com/20220215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.adaptivebiotech.com/20220215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.adaptivebiotech.com/20220215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "verboseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.adaptivebiotech.com/20220215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.adaptivebiotech.com/20220215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.adaptivebiotech.com/20220215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.adaptivebiotech.com/20220215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.adaptivebiotech.com/20220215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.adaptivebiotech.com/20220215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.adaptivebiotech.com/20220215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.adaptivebiotech.com/20220215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.adaptivebiotech.com/20220215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.adaptivebiotech.com/20220215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.adaptivebiotech.com/20220215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.adaptivebiotech.com/20220215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.adaptivebiotech.com/20220215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.adaptivebiotech.com/20220215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.adaptivebiotech.com/20220215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.adaptivebiotech.com/20220215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.adaptivebiotech.com/20220215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.adaptivebiotech.com/20220215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.adaptivebiotech.com/20220215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001564590-22-005219-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-22-005219-xbrl.zip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�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